[Pubmed] Treatment and Management of Myasthenia Gravis in Adults
Posté : 08 janv. 2024 12:00
Brain Nerve. 2024 Jan;76(1):13-18. doi: 10.11477/mf.1416202552.
ABSTRACT
Myasthenia gravis (MG), an intractable disease characterized by the production of autoantibodies against neuromuscular junction proteins, causes generalized muscle weakness. Treatment usually includes administration of steroids and immunosuppressants; however, it is difficult to achieve remission. Disease suppression and achieving the treatment goal in the early stages of MG may lead to improved long-term prognosis. In cases refractory to conventional treatments, early institution of fast-acting treatment, including intravenously administered high-dose methylprednisolone and biological treatments, is important to suppress disease activity. Following the availability of a variety of treatments and the increasing incidence of MG in the aging population, the scenario of MG treatments has changed significantly. In this study, we review the various treatment strategies and management of MG in adults.
PMID:38191134 | DOI:10.11477/mf.1416202552
Source: https://pubmed.ncbi.nlm.nih.gov/3819113 ... 9&v=2.18.0